Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-FR | Version v4-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2025-11-29 | 2025-09-23 |
| Drug Identification Number | 02491680 | 02491680 |
| Brand name | HYDROMORPHONE HYDROCHLORIDE INJECTION, USP | HYDROMORPHONE HYDROCHLORIDE INJECTION, USP |
| Common or Proper name | HYDROmorphone Hydrochloride Injection, USP 10 mg/mL, 1 mL vial | HYDROmorphone Hydrochloride Injection, USP 10 mg/mL, 1 mL vial |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | HYDROMORPHONE HYDROCHLORIDE | HYDROMORPHONE HYDROCHLORIDE |
| Strength(s) | 10MG | 10MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 10 mL | 10 mL |
| ATC code | N02AA | N02AA |
| ATC description | OPIOIDS | OPIOIDS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2025-10-12 | 2025-10-12 |
| Actual start date | ||
| Estimated end date | 2025-11-30 | 2025-11-30 |
| Actual end date | 2025-11-28 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on this product expected from October 1st to October 31st. | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on this product expected from October 1st to October 31st. |
| Health Canada comments |